stockrow
Friday 6 November 2026
Export BFRI’s income statement to Excel — free account
Biofrontera Inc.
BFRI Healthcare Drug Manufacturers Specialty & Generic
Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024.
- Revenue
- +32.9%
- EPS
- +91.2%
- Free cash flow
- +45.6%
- Total debt
- +6.50%
Quarter to June 2026, against a year earlier
0.81
0.00
0.00%
Follow BFRI
Alert me
Biofrontera Inc. (BFRI) P/E ratio
Biofrontera Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 34.0× (January 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 28.2× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 34.0×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AYTU Aytu BioPharma, Inc. compare | n/m |
| TXMD TherapeuticsMD, Inc. compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| BFRI Biofrontera Inc. | n/m |
| UPC Universe Pharmaceuticals INC compare | n/m |
| INM InMed Pharmaceuticals Inc. compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| OPTH Optimi Health Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)